AML - Acute myeloid leukemia

  1. A multicenter, double-blind, randomized, placebo-controlled, phase III study of idasanutlin, an MDM2 antagonist, with cytarabine versus cytarabine plus placebo in patients with relapsed or refractory acute myeloid leukemia (AML). MIRROS
    Primary researcher: Kimmo Porkka

  2. A phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
    Primary researcher: Kimmo Porkka

  3. An open-label, multi–center, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia who are eligible for “7+3” or “5+2” chemotherapy.
    Primary researcher: Kimmo Porkka
 

 Contact information

 
haluantutkimuspotilaaksi@hus.fi
tel. +358 50 427 0680